Disclaimer: This information is for educational and informational purposes only and is not intended as medical advice. It should not be used to diagnose or treat any medical condition. Always consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment. Clinical judgment, patient-specific factors, and the latest evidence should always guide patient care.

---

Acute Pharyngitis

Overview

• Definition: Acute pharyngitis is an acute inflammation of the pharynx and/or tonsils, characterized by a sudden onset of sore throat. It is most commonly caused by viral infections, but bacterial etiologies, predominantly Group A Streptococcus (GAS), are clinically significant due to potential suppurative and non-suppurative complications.
• Epidemiology:
  • Prevalence: Acute pharyngitis is an extremely common outpatient diagnosis, accounting for millions of healthcare visits annually.
  • Etiology Distribution:
    • Viral: Accounts for 70-85% of cases in children and 90-95% in adults. Common viruses include rhinovirus, coronavirus, adenovirus, influenza, parainfluenza, respiratory syncytial virus (RSV), and Epstein-Barr virus (EBV).
    • Bacterial: Group A Streptococcus (GAS) or Streptococcus pyogenes is responsible for 15-30% of cases in children and 5-15% in adults. Other bacterial causes (e.g., Arcanobacterium haemolyticum, Neisseria gonorrhoeae, Corynebacterium diphtheriae, Mycoplasma pneumoniae, Chlamydophila pneumoniae) are much less common.
  • Age: GAS pharyngitis is most prevalent in school-aged children (5-15 years), with peak incidence during winter and early spring months. It is uncommon in children younger than 3 years.
  • Transmission: Primarily spread by respiratory droplets through close contact with an infected individual.
• Classification:
  • Viral Pharyngitis: Most common, typically self-limiting, often associated with other cold symptoms.
  • Bacterial Pharyngitis:
    • Streptococcal Pharyngitis (GAS): The most important bacterial cause due to the risk of acute rheumatic fever (ARF) and post-streptococcal glomerulonephritis (PSGN).
    • Non-GAS Bacterial Pharyngitis: Rarer, includes other bacterial pathogens (e.g., Arcanobacterium haemolyticum, Neisseria gonorrhoeae).
  • Other Causes: Fungal (e.g., Candida in immunocompromised), allergic, irritant (e.g., GERD, smoking, post-nasal drip).

Pathophysiology

• Mechanism:
  • Viral: Viruses infect and replicate within the epithelial cells of the pharynx, leading to local inflammation, cellular damage, and activation of the immune response. This typically results in erythema, edema, and pain.
  • Bacterial (GAS): Streptococcus pyogenes colonizes the pharyngeal mucosa. It produces various virulence factors, including M protein, streptolysins (O and S), pyrogenic exotoxins (superantigens), and hyaluronidase. These factors facilitate adherence, invasion, host tissue damage, and evasion of the immune system, leading to local inflammation, exudates, and systemic symptoms (fever, malaise). The M protein and streptococcal pyrogenic exotoxins are particularly implicated in the pathogenesis of ARF and PSGN, respectively, through molecular mimicry and immune complex deposition.
  • Other: Fungal pharyngitis (e.g., candidiasis) occurs due to overgrowth in immunocompromised individuals. Non-infectious causes involve direct irritation (e.g., reflux of gastric acid, smoke) or allergic inflammatory responses.
• Risk Factors:
  • Infectious Pharyngitis:
    • Close contact: Living or working in crowded environments (schools, daycare centers, military barracks).
    • Age: School-aged children (5-15 years) for GAS.
    • Season: Winter and early spring for GAS, seasonal variations for viral respiratory pathogens.
    • Immunocompromised state: Increases risk for opportunistic infections (e.g., candidiasis).
    • Smoking/irritants: Compromises mucosal integrity.
  • Specific Risk Factors for GAS: Recent exposure to an individual with GAS pharyngitis or scarlet fever.
• Protective Factors:
  • Hand hygiene: Frequent hand washing with soap and water or alcohol-based hand rub.
  • Avoidance of close contact: Especially with sick individuals.
  • Respiratory etiquette: Covering coughs and sneezes.
  • Vaccination: Immunization against influenza and other vaccine-preventable respiratory infections can reduce the incidence of viral pharyngitis, indirectly reducing antibiotic use.
  • Adequate nutrition and rest: Support a robust immune system.

Clinical Presentation

Signs and Symptoms

• Cardinal Features:
  • Sore throat: The most common symptom, often with sudden onset, ranging from mild irritation to severe pain, especially with swallowing (odynophagia/dysphagia).
• Early Signs:
  • Viral: Often preceded or accompanied by symptoms like cough, rhinorrhea, conjunctivitis, hoarseness, oral ulcers, or diarrhea.
  • GAS: Sudden onset of sore throat, fever (often >38°C or 100.4°F), headache, abdominal pain, nausea, vomiting (especially in children), malaise.
• Advanced Signs:
  • Exudative tonsillitis: Pus or white/yellow patches on tonsils, more common in GAS but can be seen in viral (e.g., adenovirus, EBV).
  • Scarlatiniform rash: Fine, sandpaper-like rash (scarlet fever), usually beginning on the neck and chest and spreading to the trunk and extremities, with circumoral pallor and Pastia's lines (linear petechiae in skin folds). Highly suggestive of GAS.
  • Palatal petechiae: Small red spots on the soft palate, more common in GAS.
  • Anterior cervical lymphadenitis: Tender, enlarged lymph nodes in the anterior neck.
• Atypical Presentations:
  • Infants/Toddlers (GAS): May present with fever, irritability, decreased appetite, and mild coryza, without the classic sore throat complaint. Abdominal pain, nausea, and vomiting can be prominent.
  • Gonococcal pharyngitis: Often asymptomatic, or mild sore throat, can present with exudates. Requires specific risk factor assessment (oral sexual contact).
  • Diphtheria: Grayish pseudomembrane that adheres tightly to the tonsils, pharynx, or nasal passages; removal causes bleeding. Associated with severe systemic toxicity. Rare due to vaccination.
  • Mono (EBV): Prolonged severe sore throat, significant fatigue, generalized lymphadenopathy (posterior cervical), splenomegaly, hepatomegaly, often with significant tonsillar exudates.

Physical Examination

• Inspection:
  • Oropharynx: Erythema (redness) of the tonsils and pharynx is common. Presence of tonsillar exudates (white, yellow, or grayish patches or streaks) suggests bacterial infection but can be viral. Swelling (edema) of the uvula.
  • Skin: Scarlatiniform rash (sandpaper texture, blanching) with circumoral pallor and Pastia's lines strongly suggests scarlet fever (GAS).
  • Conjunctiva: Conjunctivitis is more indicative of viral etiology (e.g., adenovirus).
  • Oral mucosa: Oral ulcers (herpangina, HSV) or vesicular lesions (HSV) indicate viral cause.
• Palpation:
  • Lymph nodes: Tender, enlarged anterior cervical lymph nodes are common in GAS. Posterior cervical lymphadenopathy is more suggestive of viral (e.g., EBV).
  • Abdomen: Splenomegaly or hepatomegaly may be present in EBV mononucleosis.
• Special Tests:
  • No specific "special tests" for acute pharyngitis on physical exam beyond careful inspection and palpation. The Modified Centor/McIsaac score is a clinical decision rule rather than a physical test.

Diagnostic Approach

History Taking

• Key Questions:
  • Onset and duration: Sudden vs. gradual.
  • Severity of sore throat: Pain with swallowing, interference with eating/drinking.
  • Associated symptoms:
    • Fever/chills: Indicates systemic illness.
    • Cough, rhinorrhea, conjunctivitis, hoarseness, oral ulcers, diarrhea: Strong predictors of viral etiology (suggests not GAS).
    • Headache, abdominal pain, nausea/vomiting: Common in GAS, especially in children.
    • Rash: Suggests scarlet fever (GAS).
    • Fatigue, malaise, myalgia: General viral or bacterial symptoms.
  • Exposures: Close contact with someone with strep throat or scarlet fever. Daycare/school exposures.
  • Past medical history: History of rheumatic fever, recurrent strep.
  • Immunization status: Diphtheria, influenza.
  • Risk factors for specific pathogens: Oral sexual contact (gonorrhea), immunocompromised state (fungal).
• Red Flags: Warning signs requiring urgent attention:
  • Dyspnea or stridor: Suggests upper airway obstruction (e.g., epiglottitis, peritonsillar abscess, retropharyngeal abscess, diphtheria).
  • Drooling or inability to swallow secretions: Indicates severe odynophagia or airway compromise.
  • Muffled voice ("hot potato voice"): Classic for peritonsillar abscess.
  • Neck stiffness/rigidity: Especially with fever, may indicate meningitis or deep neck space infection.
  • Unilateral severe sore throat: Suggests peritonsillar abscess.
  • Toxic appearance: Lethargy, poor perfusion, altered mental status.
  • Severe trismus: Difficulty opening the mouth, suggestive of deep neck space infection.
  • History of recent foreign body ingestion: Especially in children.

Laboratory Tests

The primary goal of testing is to identify or rule out Group A Streptococcus (GAS) due to its treatable nature and potential for serious complications. - First-Line: * Modified Centor/McIsaac Score: Clinical prediction rule used to estimate the probability of GAS pharyngitis and guide testing decisions. * Criteria (1 point for each): * Tonsillar exudates * Swollen, tender anterior cervical lymph nodes * Absence of cough * History of fever (oral temperature ≥100.4°F or 38°C) * Age 3-14 years (+1 point) * Age 15-44 years (0 points) * Age ≥45 years (-1 point) * Interpretation and Action (IDSA 2012 guidelines): * Score 0-1: Low probability of GAS. No routine testing or antibiotics needed. (Sensitivity <80%, Specificity >50%) * Score 2-3: Intermediate probability. Rapid antigen detection test (RADT) recommended. If positive, treat with antibiotics. If negative, throat culture can be performed (especially in areas with high incidence of ARF or if RADT sensitivity is low). (Sensitivity 80-95%, Specificity 90-95%) * Score 4-5: High probability. RADT recommended. If positive, treat with antibiotics. If RADT is not available, empiric antibiotic treatment may be considered in regions with high ARF rates, but RADT is preferred. (Sensitivity 90-95%, Specificity 90-95%) * Rapid Antigen Detection Test (RADT): Detects GAS carbohydrate antigen from a pharyngeal swab. * Advantages: Quick results (minutes), allows for timely treatment. * Disadvantages: Sensitivity 70-90% (meaning false negatives can occur), Specificity 95-99% (false positives are rare). * Action: A positive RADT in patients with symptoms is sufficient for diagnosis and initiation of treatment. A negative RADT in children and adolescents (up to age 18) should ideally be confirmed with a throat culture due to the risk of ARF if GAS is missed. In adults, a negative RADT does not typically require confirmatory culture, as the risk of ARF is very low. - Confirmatory: * Throat Culture: Considered the "gold standard" for diagnosing GAS pharyngitis. * Advantages: High sensitivity (90-95%) and specificity (99%). * Disadvantages: Takes 24-48 hours for results, delaying treatment initiation. * Action: Recommended to confirm negative RADT in children and adolescents, or if RADT is unavailable. - Other Tests (if clinically indicated): * Monospot test or EBV serology: If infectious mononucleosis is suspected (prolonged symptoms, marked fatigue, generalized lymphadenopathy, splenomegaly, atypical lymphocytes on CBC). * Complete Blood Count (CBC): May show leukocytosis with neutrophilia in bacterial infections, or lymphocytosis with atypical lymphocytes in viral mononucleosis. * ASO titer / Anti-DNase B: For retrospective diagnosis of recent GAS infection (e.g., in suspected ARF or PSGN workup). Not for acute diagnosis. * Nucleic Acid Amplification Tests (NAATs): Highly sensitive and specific for GAS, providing results faster than culture. Becoming more available and may replace RADT/culture combination. * Gonococcal culture/NAAT: If gonococcal pharyngitis is suspected (risk factors: oral sexual contact, concurrent anogenital infection). * Diphtheria culture: If diphtheria is suspected (travel history, unvaccinated, severe systemic symptoms, pseudomembrane).

Imaging

• Recommended: Imaging is generally not indicated for uncomplicated acute pharyngitis.
• Advanced: Imaging is reserved for suspected complications or alternative diagnoses when there are red flag symptoms.
  • Lateral neck radiograph (soft tissue neck X-ray): Can help identify retropharyngeal or peritonsillar abscess, epiglottitis (thumb sign), or foreign bodies. Less sensitive than CT.
  • Computed Tomography (CT) scan of the neck with intravenous contrast: The imaging modality of choice for suspected deep neck space infections (e.g., peritonsillar abscess, retropharyngeal abscess, parapharyngeal abscess) to delineate the extent of infection and guide surgical management.
  • Ultrasound: Can be used by experienced operators to differentiate cellulitis from abscess in the peritonsillar area and guide aspiration.

Management

Acute Management

• Immediate:
  • Symptomatic relief: Focus on alleviating pain and fever.
    • Analgesics/Antipyretics:
      • Acetaminophen (paracetamol): Adults: 325-1000 mg every 4-6 hours, Max 4g/day. Children: 10-15 mg/kg every 4-6 hours, Max 75 mg/kg/day (not to exceed 4000 mg/day).
      • NSAIDs (e.g., Ibuprofen): Adults: 200-400 mg every 4-6 hours, Max 1200 mg/day (OTC) or 3200 mg/day (prescription). Children: 5-10 mg/kg every 6-8 hours, Max 40 mg/kg/day.
    • Local anesthetics: Lozenges (e.g., benzocaine, dyclonine), sprays (e.g., benzydamine, chloraseptic), gargles (e.g., salt water, viscous lidocaine 2% - use with caution in children due to systemic absorption risk).
• Stabilization: Uncomplicated pharyngitis does not require stabilization.
• Emergency:
  • Airway management: For patients presenting with severe airway compromise (e.g., stridor, dyspnea, drooling, severe odynophagia) due to epiglottitis or deep neck space infections. May require intubation or cricothyrotomy.
  • Fluid resuscitation: For severe dehydration secondary to inability to swallow fluids.
  • Referral to ENT/Surgery: For drainage of abscesses (e.g., peritonsillar, retropharyngeal).

Chronic Management

Acute pharyngitis is not a chronic condition. Management focuses on treating the acute episode and preventing complications. Recurrent episodes may prompt investigation for underlying causes or consider tonsillectomy in specific criteria.

Pharmacological

• Treatment for Group A Streptococcal Pharyngitis:
  • Goals: Prevent acute rheumatic fever (ARF), reduce symptom duration, prevent suppurative complications (e.g., peritonsillar abscess), and reduce transmission. Treatment must be initiated within 9 days of symptom onset to effectively prevent ARF.
  • First-Line (Penicillins): Preferred agents due to efficacy, safety, narrow spectrum, and low cost.
    • Penicillin V (oral):
      • Adults: 500 mg 2-3 times daily for 10 days.
      • Children: 250 mg 2-3 times daily for 10 days, or 12 mg/kg/dose 2-3 times daily for 10 days (max 500 mg/dose).
    • Amoxicillin (oral): Often preferred in children due to taste and twice-daily dosing.
      • Adults: 500 mg 2-3 times daily for 10 days, or 750-1000 mg once daily for 10 days (if extended-release formulation, follow specific instructions).
      • Children: 50 mg/kg once daily (max 1000 mg/day) or 25 mg/kg twice daily (max 500 mg/dose) for 10 days.
    • Benzathine Penicillin G (intramuscular): For patients with poor adherence or vomiting.
      • Adults: 1.2 million units IM as a single dose.
      • Children (≥27 kg): 1.2 million units IM as a single dose.
      • Children (<27 kg): 600,000 units IM as a single dose.
  • Second-Line (Cephalosporins): For patients with non-anaphylactic penicillin allergy.
    • Cephalexin (oral):
      • Adults: 500 mg twice daily for 10 days.
      • Children: 20 mg/kg twice daily (max 500 mg/dose) for 10 days.
    • Cefadroxil (oral):
      • Adults: 1000 mg once daily for 10 days.
      • Children: 30 mg/kg once daily (max 1000 mg/day) for 10 days.
  • Macrolides/Azalides (for severe penicillin allergy or intolerance): Note: Resistance to macrolides among GAS is increasing in some regions.
    • Azithromycin (oral):
      • Adults: 500 mg on day 1, then 250 mg once daily on days 2-5 (total 5 days).
      • Children: 12 mg/kg once daily (max 500 mg/day) for 5 days.
    • Clarithromycin (oral):
      • Adults: 250 mg twice daily for 10 days.
      • Children: 7.5 mg/kg twice daily (max 250 mg/dose) for 10 days.
  • Clindamycin (for penicillin-allergic patients with macrolide resistance or intolerance): Effective against GAS and often used when penicillin treatment fails or in recurrent cases (due to activity against co-pathogens that may produce beta-lactamase).
    • Adults: 300 mg three times daily for 10 days.
    • Children: 7 mg/kg three times daily (max 300 mg/dose) for 10 days.
• Treatment for Viral Pharyngitis: No specific antiviral agents are typically used, as it is self-limiting. Management is purely symptomatic with analgesics/antipyretics and non-pharmacological measures.
• Other Bacterial Causes:
  • Gonococcal pharyngitis: Ceftriaxone 500 mg IM single dose (for patients <150 kg) or 1 g IM single dose (for patients ≥150 kg). Azithromycin is no longer routinely recommended concurrently due to increasing resistance.
  • Diphtheria: Diphtheria antitoxin + penicillin or erythromycin. Requires immediate consultation with infectious disease specialist and public health.
  • Mycoplasma/Chlamydophila: Macrolides (azithromycin or erythromycin) or tetracyclines (doxycycline, in children >8 years).

Non-pharmacological

• Rest: Adequate rest can aid recovery.
• Hydration: Drink plenty of fluids (water, warm tea, broths) to prevent dehydration and soothe the throat.
• Humidifier: Cool mist humidifier can moisten the air and soothe irritated mucous membranes.
• Saltwater gargles: Warm salt water (1/4 to 1/2 teaspoon of salt in 8 ounces of warm water) gargles several times a day can help reduce throat discomfort.
• Lozenges/Hard candies: Can stimulate saliva production and provide temporary relief from throat dryness and pain.
• Avoid irritants: Smoking, exposure to secondhand smoke, and environmental pollutants.

Treatment Algorithms

1. Assess clinical likelihood of GAS pharyngitis using Modified Centor/McIsaac score:

   • Score 0-1: Low probability. No testing. Symptomatic treatment only.
   • Score 2-3: Intermediate probability. Perform RADT.
     • If RADT positive: Treat with antibiotics for GAS.
     • If RADT negative: Perform throat culture (especially in children/adolescents). If culture positive, treat with antibiotics. If culture negative, symptomatic treatment only.
   • Score 4-5: High probability. Perform RADT.
     • If RADT positive: Treat with antibiotics for GAS.
     • If RADT negative: Perform throat culture (especially in children/adolescents). If culture positive, treat with antibiotics. If culture negative, symptomatic treatment only. (In high ARF prevalence areas, empiric treatment can be considered while awaiting culture, but RADT is preferred.)

2. Confirming GAS: A positive RADT or throat culture confirms GAS pharyngitis.

3. Initiate antibiotic treatment for GAS: Refer to pharmacological section for dosages and duration.

4. Counseling: Educate patients on completing the full course of antibiotics, even if symptoms improve, to prevent ARF. Advise on symptomatic relief measures.

• First-Line (GAS): Penicillin V or Amoxicillin for 10 days.
• Second-Line (GAS):
  • Cephalosporins (e.g., Cephalexin) for 10 days (non-anaphylactic penicillin allergy).
  • Macrolides (e.g., Azithromycin for 5 days, Clarithromycin for 10 days) or Clindamycin for 10 days (severe penicillin allergy or macrolide resistance concerns).
• Refractory Cases (GAS):
  • If symptoms persist or recur after a full course of appropriate antibiotics:
    • Re-evaluate diagnosis: Was it truly GAS? Could it be a non-streptococcal infection (e.g., viral, EBV) or non-infectious cause?
    • Check adherence: Was the full course of antibiotics completed?
    • Consider carrier state: A small percentage of individuals may remain GAS carriers after treatment and may not require further antibiotics unless symptomatic or if there is a history of ARF in the household.
    • Alternative antibiotics: Consider Clindamycin or Amoxicillin/clavulanate for 10 days, as these agents cover beta-lactamase-producing oral flora that may "shield" GAS from penicillin.
    • Consider repeat testing: To confirm persistent GAS infection if treatment failure is suspected.
    • Peritonsillar abscess: Rule out local complications.

Complications

• Common (Suppurative):
  • Peritonsillar Abscess (Quinsy): Collection of pus behind the tonsil. Symptoms include severe unilateral sore throat, fever, "hot potato" voice, trismus, and uvular deviation. Requires drainage.
  • Retropharyngeal Abscess: More serious, can cause airway obstruction. Symptoms include high fever, neck stiffness, drooling, dysphagia, and inspiratory stridor. More common in young children. Requires drainage.
  • Otitis Media, Sinusitis: Spread of infection to adjacent structures.
• Serious (Non-suppurative): Primarily associated with GAS.
  • Acute Rheumatic Fever (ARF): A severe inflammatory disease affecting the heart (rheumatic heart disease), joints (polyarthritis), brain (Sydenham chorea), and skin (erythema marginatum, subcutaneous nodules). It is preventable with timely antibiotic treatment of GAS pharyngitis.
  • Post-streptococcal Glomerulonephritis (PSGN): An immune-mediated renal disease characterized by hematuria, proteinuria, edema, and hypertension. While antibiotic treatment for GAS prevents ARF, it does not prevent PSGN. However, PSGN is not associated with specific M-protein types and can follow skin infections as well.
  • Invasive Group A Streptococcal Disease (iGAS): Rare but severe, includes necrotizing fasciitis, streptococcal toxic shock syndrome, and bacteremia.
• Long-term:
  • Recurrent Acute Pharyngitis/Tonsillitis: Frequent episodes of pharyngitis, often leading to consideration of tonsillectomy in severe, recurrent cases based on specific criteria (e.g., Paradise criteria).
  • Chronic carrier state: Asymptomatic carriage of GAS, usually not associated with complications or need for treatment.

Prognosis

• Factors:
  • Etiology: Viral pharyngitis is self-limiting with excellent prognosis. GAS pharyngitis also has an excellent prognosis if treated appropriately.
  • Timeliness of treatment: Prompt antibiotic treatment of GAS pharyngitis significantly reduces the risk of ARF.
  • Presence of complications: Complications like peritonsillar abscess or ARF can significantly worsen prognosis if not managed effectively.
  • Patient comorbidities: Immunocompromised patients may have more severe or prolonged infections.
• Survival: Excellent for uncomplicated acute pharyngitis. Mortality is rare and usually associated with severe complications (e.g., airway obstruction from deep neck space infection, severe iGAS).
• Quality of Life: Temporarily impaired during the acute illness due to pain, fever, and malaise. With appropriate management, full recovery and return to baseline quality of life are expected. Untreated or complicated GAS can lead to significant long-term morbidity (e.g., rheumatic heart disease).

Prevention

• Primary: Preventing initial occurrence of infection.
  • Hand hygiene: Frequent and thorough hand washing with soap and water, especially after coughing, sneezing, and before eating.
  • Avoid close contact: Limit proximity to individuals who are sick.
  • Respiratory etiquette: Cover coughs and sneezes with a tissue or elbow.
  • Avoid sharing: Do not share eating utensils, cups, or food with others.
  • Environmental hygiene: Regular cleaning of frequently touched surfaces.
  • Vaccination: Influenza vaccine helps prevent viral pharyngitis caused by influenza. No vaccine is currently available for GAS.
• Secondary: Early detection and intervention to prevent complications.
  • Prompt diagnosis and treatment of GAS pharyngitis: Timely use of antibiotics for confirmed GAS infection prevents ARF.
  • Education: Patients should be educated on the importance of completing the full course of antibiotics, even if symptoms resolve, to eradicate the bacteria and prevent ARF.
• Tertiary: Preventing recurrence or worsening of existing conditions.
  • Secondary prophylaxis for ARF: For individuals who have had a prior episode of ARF, continuous antibiotic prophylaxis (typically penicillin G benzathine IM every 3-4 weeks) is crucial to prevent recurrent ARF and progression of rheumatic heart disease. Duration depends on presence and severity of cardiac involvement.
  • Tonsillectomy: May be considered in carefully selected patients with recurrent, severe episodes of pharyngitis that significantly impair quality of life, typically meeting specific Paradise criteria.

Special Populations

• Pediatric:
  • Higher incidence of GAS: Most common in children 5-15 years.
  • Symptoms: Younger children (<3 years) may present atypically with fever, irritability, rhinorrhea, decreased appetite, abdominal pain, nausea, and vomiting rather than the classic sore throat.
  • Testing: Due to the higher risk of ARF, a negative RADT in children and adolescents requires confirmatory throat culture.
  • Dosing: Antibiotic dosages are weight-based (see pharmacological section).
  • Adherence: Ensuring full 10-day course of antibiotics is critical and can be challenging; IM penicillin may be an option.
• Geriatric:
  • Lower incidence of GAS: Less common in adults over 45 years.
  • Clinical presentation: May be atypical or masked by comorbidities.
  • Consider other causes: Less common pathogens, non-infectious causes (e.g., GERD, post-nasal drip) may be more prevalent.
  • Centor/McIsaac Score: Age >45 years subtracts a point, reflecting lower GAS probability.
  • Medication considerations: Polypharmacy, renal/hepatic impairment may necessitate dose adjustments or avoidance of certain antibiotics.
• Pregnancy:
  • Diagnosis: Same as general population.
  • Treatment for GAS: Penicillins (Penicillin V, Amoxicillin) are safe and effective. Cephalexin is also safe. Macrolides (Erythromycin, Azithromycin) are generally considered safe but preferred to avoid if alternatives exist due to potential for fetal cardiac effects (erythromycin estolate) or increasing GAS resistance. Clindamycin is also considered safe. Avoid tetracyclines and fluoroquinolones.
  • Importance of treatment: Untreated GAS in pregnancy poses a risk of peripartum complications (e.g., puerperal sepsis), although ARF risk is low.
• Comorbidities:
  • Immunocompromised patients: Higher risk for opportunistic infections (e.g., fungal pharyngitis, especially Candida), more severe or prolonged infections. May require broader diagnostic workup and specific antifungal/antiviral therapy.
  • Diabetes mellitus: Increased risk of more severe infections and potential for deeper space infections.
  • History of Rheumatic Fever: Requires prompt and aggressive treatment of GAS and ongoing secondary prophylaxis.
  • Renal/Hepatic impairment: Adjust antibiotic dosages as needed.

Clinical Pearls

• Diagnostic:
  • "No cough, no cold": A strong indicator for GAS. If a patient presents with prominent cough, rhinorrhea, and other cold symptoms, GAS is highly unlikely.
  • Centor/McIsaac score: A valuable clinical tool to guide testing but is not definitive; clinical judgment remains paramount. Remember the age adjustment!
  • Always test children/adolescents: Due to the risk of ARF, all symptomatic children and adolescents with a score of ≥2 should be tested for GAS.
  • Adults vs. children: A negative RADT in adults generally does not require a confirmatory culture due to very low ARF risk.
  • EBV Mononucleosis masquerade: Be aware of EBV as a cause of exudative pharyngitis, especially with generalized lymphadenopathy and significant fatigue. Avoid amoxicillin in suspected EBV as it can cause a rash.
• Treatment:
  • Full 10-day course: Emphasize completion of the entire 10-day antibiotic course for GAS to ensure eradication and prevent ARF, even if symptoms improve earlier.
  • Steroids: A short course of corticosteroids (e.g., dexamethasone) can provide rapid symptomatic relief for severe exudative pharyngitis with significant odynophagia or airway swelling, but it is not routinely recommended for mild cases and does not prevent complications.
  • Symptomatic relief is key: For viral pharyngitis, manage expectations and provide robust advice on pain relief and comfort measures.
• Pitfalls:
  • Over-prescribing antibiotics: Treating viral pharyngitis with antibiotics contributes to antibiotic resistance and unnecessary side effects.
  • Missing GAS: Especially in children, can lead to ARF.
  • Under-treating GAS: Incomplete antibiotic courses can lead to treatment failure, recurrence, and potentially ARF.
  • Misdiagnosing complications: Failure to recognize red flags for deep neck space infections or epiglottitis can have dire consequences.
  • Ignoring risk factors for specific pathogens: Missing gonorrhea or diphtheria due to lack of historical inquiry.
  • Relying solely on clinical scores: Centor/McIsaac scores are predictive tools, not diagnostic. Always use in conjunction with testing and clinical judgment.

Recent Updates

• Guidelines: The 2012 Infectious Diseases Society of America (IDSA) guidelines for the diagnosis and management of Group A Streptococcal Pharyngitis remain a cornerstone. However, ongoing research and regional variations influence practice. The 2021 AHA/ACC Guidelines for the Diagnosis and Management of Patients With Rheumatic Heart Disease also reinforce the importance of GAS treatment.
• Evidence:
  • Increased use of NAATs: There's a growing trend towards using nucleic acid amplification tests (NAATs) for GAS detection. These tests offer higher sensitivity and specificity than RADTs, with rapid turnaround times, potentially replacing the RADT + culture algorithm in some settings.
  • Macrolide resistance: Surveillance data continues to show increasing rates of macrolide resistance among GAS strains in various regions, reinforcing penicillin and amoxicillin as first-line therapies.
  • Shortened antibiotic courses: While 10-day courses remain standard for penicillin/amoxicillin, 5-day courses of azithromycin and certain cephalosporins have been shown to be effective for GAS in some studies, but generalizability and ARF prevention efficacy for all agents and populations require further evaluation. IDSA currently recommends a 10-day course for penicillin/amoxicillin.
• Controversies:
  • The role of confirmatory culture for negative RADT in adults: While IDSA guidelines do not recommend it, some clinicians may still perform it in specific situations or high-risk populations, though the risk of ARF in adults is exceedingly low.
  • Empiric antibiotic treatment for high Centor scores: Some clinicians might empirically treat patients with high Centor scores without testing, particularly in contexts where follow-up is uncertain. However, the current standard of care generally favors testing to reduce unnecessary antibiotic use.
  • Routine testing for GAS in children <3 years: GAS pharyngitis is rare and ARF is extremely rare in this age group, leading to debate on the utility of routine testing unless there's a clear epidemiological link to a known GAS exposure or high clinical suspicion.

Key References

• Guidelines:
  • Shulman ST, Bisno AL, Clegg HW, et al. Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis: 2012 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2012;55(10):e86-e102.
  • Gerber MA, Baltimore RT, Eaton CB, et al. Prevention of Rheumatic Fever and Diagnosis and Treatment of Acute Streptococcal Pharyngitis: A Scientific Statement From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: Endorsed by the American Academy of Pediatrics. Circulation. 2009;119(11):1541-1551.
  • NICE Guideline NG89: Sore throat - antimicrobial prescribing. National Institute for Health and Care Excellence, UK. Published 2018, last updated 2022.
• Studies:
  • Bisno AL, Gerber MA, Gwaltney JM Jr, Kaplan EL, Schwartz RH. Diagnosis and management of Group A streptococcal pharyngitis: a practice guideline. Infectious Diseases Society of America. Clin Infect Dis. 1997;25(3):574-583. (Though older, foundational for understanding GAS management principles).
  • McIsaac WJ, White D, Tannenbaum D, Low DE. A clinical score to identify children at high risk for streptococcal pharyngitis: a valid tool for office use. Arch Pediatr Adolesc Med. 1814;158(7):728-732. (Source for McIsaac score).
• Reviews:
  • Choby BA. Diagnosis and treatment of streptococcal pharyngitis. Am Fam Physician. 2009;79(5):383-390.
  • Humphries RM. Rapid Diagnostics for Group A Streptococcus. Clin Infect Dis. 2020;71(Supplement_2):S105-S110.